Prakiraan pendapatan perusahaan: ProQR Therapeutics NV (PRQR)

Logo perusahaan publik ProQR Therapeutics (PRQR)

The development of ProQR Therapeutics N.V. (PRQR) relies on the success of RNA therapy and research funding. The company's planned sales level on this GURU.Markets platform chart reflects business dynamics, where 0.02 expresses the current metric value. Optimization is achieved through the proprietary Axiomer system, which creates a closed innovation loop, as well as through the use of diversified international cold chains to ensure stable material delivery.

PRQR - Prakiraan volume dodolan proqr.com ing rentang 04.07.2022 - 15.11.2026

Ringkesan rincian data analitis ProQR Therapeutics (PRQR)

Analisis komprehensif perusahaan:ProQR Therapeutics PRQR
Produk merek proqr.com

ProQR Therapeutics N.V. (PRQR) innovations in RNA editing for the treatment of orphan diseases make the target product realization level an indicator of therapy demand within narrow niches of genetic medicine. This metric aggregates the market consensus on future inflows, transforming transaction data and logistics costs into a business sustainability forecast, which allows investors to promptly assess drawdown risks or the company's margin of safety.

Pesaing wigati

Volume dodolan mangsa ngarep perusahaan TEM (Tempus AI)|Dodolan mangsa ngarep perusahaan Qiagen Group|Prakiraan pendapatan perusahaan Ionis Pharma IONS|RGEN - Volume dodolan mangsa ngarep perusahaan|RNA - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan RARE (Ultragenyx)|Volume dodolan mangsa ngarep perusahaan BEAM|Prakiraan volume dodolan Sarepta Corp|Prakiraan pendapatan perusahaan Twist Bioscience, Inc. (TWST)|Volume dodolan mangsa ngarep perusahaan 10x Genomics TXG|Prakiraan pendapatan perusahaan Intellia Therapeutics NTLA|Prakiraan volume pendapatan perusahaan STOK (Stoke Therapeutics, Inc.)|BLFS - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Wave Pharma|mazetx.com (MAZE) - Prakiraan pendapatan perusahaan|SION - Dodolan mangsa ngarep perusahaan|PRME (Prime Medicine Inc) - Prakiraan volume dodolan|Taysha Gene Therapies, Inc. - Pendapatan sing dikarepake perusahaan|Prakiraan volume dodolan QURE|MGTX: Pendapatan sing dikarepake perusahaan|Prakiraan pendapatan perusahaan REGENXBIO RGNX|SLDB: Prakiraan pendapatan perusahaan|OCGN: Volume dodolan mangsa ngarep perusahaan|PACB - Prakiraan volume dodolan|BNTC (Benitec Corp) - Volume dodolan mangsa ngarep perusahaan|Prakiraan dodolan perusahaan Design Corp DSGN|Prakiraan pendapatan perusahaan Rocket Pharmaceuticals|Prakiraan volume dodolan 4D Molecular Therapeutics, Inc.|Prakiraan pendapatan perusahaan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan EDIT (Editas Medicine, Inc.)|Prakiraan volume dodolan Silence Therapeutics Corp SLN|CDXS - Prakiraan pendapatan perusahaan|SGMO (Sangamo Therapeutics) - Prakiraan pendapatan perusahaan|NAUT: Prakiraan volume dodolan|Prakiraan pendapatan perusahaan MGX|DTIL (precisionbiosciences.com) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan GBIO (Generation Bio Co.)|Prakiraan pendapatan perusahaan Boundless Bio (BOLD)|Exicure - Prakiraan pendapatan perusahaan|Prakiraan volume dodolan IMNN (imunon.com)|Dodolan mangsa ngarep perusahaan Phio Pharmaceuticals (PHIO)|MBIO: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Prakiraan pendapatan perusahaan|APDN - Dodolan mangsa ngarep perusahaan|Volume dodolan mangsa ngarep perusahaan BLUE|Prakiraan volume dodolan immunoprecise.com|Prakiraan volume dodolan OMGA|Dodolan mangsa ngarep perusahaan Singular Genomics Corp|Regulus Therapeutics - Volume dodolan mangsa ngarep perusahaan|SYRS (Syros Pharmaceuticals) - Pendapatan sing dikarepake perusahaan|Telesis Bio Inc. - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan TCON (TRACON Pharmaceuticals Inc.)|UBX: Prakiraan volume dodolan